UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in charter)
|
| |||
(State or other jurisdiction of incorporation) |
| (Commission File Number) |
| (IRS Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
(
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act: | ||
Title of each class | Trading Symbols | Name of exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | |
Item 2.02. Results of Operations and Financial Condition.
On May 7, 2020, we issued a press release reporting, among other things, our sales and operating results for the three-month period ended March 31, 2020. A copy of the press release is furnished as Exhibit 99.1 to this report.
In accordance with general instruction B.2 to Form 8-K, the information included in this Item 2.02, and the exhibits attached hereto, shall be deemed to be “furnished” and shall not be deemed to be “filed” with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.
Item 9.01. Financial Statements and Exhibits.
Exhibit No. |
| Description |
|
|
|
99.1 |
| |
104 |
| The cover page from this Current Report on Form 8-K, formatted as Inline XBRL. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| GLOBUS MEDICAL, INC. |
|
| (Registrant) |
|
|
|
Dated: | May 7, 2019 | /s/ KEITH PFEIL |
|
|
|
|
| Keith Pfeil |
|
| Senior Vice President |
|
| Chief Financial Officer |
|
| Chief Accounting Officer |
|
| (Principal Financial Officer) |
|
|
|
Globus Medical Reports First Quarter 2020 Results
AUDUBON, PA, May 7, 2020: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the first quarter ended March 31, 2020.
|
· |
Worldwide sales were $190.6 million, an increase of 4.2% as reported |
|
· |
First quarter net income was $25.9 million |
|
· |
Diluted earnings per share (EPS) was $0.25 and non-GAAP diluted EPS was $0.29 |
|
· |
Non-GAAP adjusted EBITDA was 26.5% of sales |
“The COVID-19 pandemic presents one of the greatest healthcare challenges we have faced in recent history. We remain diligent in our commitment to protect the health of our people, support our surgeons and patients in need, and keep our company strong,” said Dave Demski, President and CEO. As we chart a course through this extraordinary and challenging time together, we have been heartened at every turn by the understanding, cooperation and support from so many people in the Globus Medical community. We are deeply thankful to our employees, their families, surgeons, suppliers and other parties for pulling together under such trying and fluid circumstances. Globus Medical continues to work closely with federal, state and local authorities to ensure alignment with their efforts.
“Our conservative financial philosophy has positioned us well to ride out this difficult time without having to reduce our commitment to any important long-term growth initiatives. We launched three new Spine products in the first quarter, and launched two additional innovative products in April. We are seeing great uptake from several products in our HEDRON line of 3D printed interbody spacers, the most comprehensive portfolio of 3D printed spacers in the industry. During the quarter, we also launched SABLE, our fourth generation expandable MIS TLIF interbody spacer that was met with strong demand and great feedback. We look forward to bringing additional innovation to market in coming quarters as well,” said Demski.
Worldwide sales for the first quarter were $190.6 million, an increase of 4.2% over the first quarter of 2019 on an as-reported basis and 4.4% on a constant currency basis. We estimate the negative sales impact of COVID-19 to be approximately $20 million in the quarter. First quarter sales in the U.S., including robotics, increased by 7.4% compared to the first quarter of 2019. International sales decreased by 9.3% over the first quarter of 2019 on an as-reported basis and 8.3% on a constant currency basis.
First quarter GAAP net income was $25.9 million, a decrease of 21.9% over the same period last year. Diluted EPS for the first quarter was $0.25, as compared to $0.33 for the first quarter 2019. Non-GAAP diluted EPS for the first quarter was $0.29, compared to $0.36 in the first quarter of 2019, a decrease of 18.9%.
The Company generated net cash provided by operating activities of $42.3 million and non-GAAP free cash flow of $20.0 million in the first quarter, and ended the quarter with cash, cash equivalents and marketable securities of $657.0 million. The Company remains debt free.
2020 Annual Guidance
On April 16, 2020, due to the rapidly evolving environment and continued uncertainties resulting from the COVID-19 pandemic, Globus Medical withdrew previously announced full year 2020 guidance. At this time, Globus Medical cannot predict the specific extent, or duration, of the impact of COVID-19 on its financial and operating results.
Conference Call Information
Globus Medical will hold a teleconference to discuss its 2020 first quarter results with the investment community at 4:30 p.m. Eastern Time today. Globus invites all interested parties to join the call by dialing:
1-855-533-7141 United States Participants
1-720-545-0060 International Participants
There is no pass code for the teleconference.
For interested parties who do not wish to ask questions, the teleconference will be webcast live and may be accessed through a link on the Globus Medical website at www.globusmedical.com/investors.
The call will be archived until Thursday, May 14, 2020. The audio archive can be accessed by calling 1-855-859-2056 in the U.S. or 1-404-537-3406 from outside the U.S. The passcode for the audio replay is 209-4398.
Based in Audubon, Pennsylvania, Globus Medical, Inc. was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at www.globusmedical.com.
To supplement our financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), management uses certain non-GAAP financial measures. For example, non-GAAP adjusted EBITDA, which represents net income before interest income, net and other non-operating expenses, provision for income taxes, depreciation and amortization, stock-based compensation, provisions for litigation, and acquisition related costs/licensing, and net gain from the sale of assets, is useful as an additional measure of operating performance, and particularly as a measure of comparative operating performance from period to period, as it is reflective of changes in pricing decisions, cost controls and other factors that affect operating performance, and it removes the effect of our capital structure, asset base, income taxes and interest income and expense. Our management also uses non-GAAP adjusted EBITDA for planning purposes, including the preparation of our annual operating budget and financial projections. Provision for litigation represents costs incurred for litigation settlements or unfavorable verdicts when the loss is known or considered probable and the amount can be reasonably estimated, or in the case of a favorable settlement, when income is realized. Acquisition-related costs/licensing represents the change in fair value of business acquisition-related contingent consideration; costs related to integrating recently acquired businesses, including but not limited to costs to exit or convert contractual obligations, severance, and information system conversion; and specific costs related to the consummation of the acquisition process such as banker fees, legal fees, and other acquisition-related professional fees, as well as one-time licensing fees. Net gain from sale of assets represents the gain on sale of assets and the offsetting impact of costs incurred through the sale.
In addition, for the period ended March 31, 2020 and for other comparative periods, we are presenting non-GAAP net income and non-GAAP diluted earnings per share, which represent net income and diluted earnings per share excluding the provision for litigation, amortization of intangibles, acquisition-related costs/licensing, net gain from the sale of assets, impacts of the U.S. Tax Reform Act and the tax effects of such adjustments. We believe these non-GAAP measures are also useful indicators of our operating performance, and particularly as additional measures of comparative operating performance from period to period as they remove the effects of litigation, amortization of intangibles, acquisition-related costs/licensing, net gain from the sale of assets and the tax effects of such adjustments, which we believe are not reflective of underlying business trends. Additionally, for the periods ended March 31, 2020 and for other comparative periods, we also define the non-GAAP measure of free cash flow as the net cash provided by operating activities, adjusted for the impact of restricted cash, less the cash impact of purchases of property and equipment. We believe that this financial measure provides meaningful information for evaluating our overall financial performance for comparative periods as it facilitates an assessment of funds available to satisfy current and future obligations and fund acquisitions. Furthermore, the non-GAAP measure of constant currency sales growth is calculated by translating current year sales at the same average exchange rates in effect during the applicable prior year period. We believe constant currency sales growth provides insight to the comparative increase or decrease in period sales, in dollar and percentage terms, excluding the effects of fluctuations in foreign currency exchange rates.
Non-GAAP adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings per share, free cash flow and constant currency sales growth are not calculated in conformity with U.S. GAAP. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for financial measures prepared in accordance with U.S. GAAP. These measures do not include certain expenses that may be necessary to evaluate our liquidity or operating results. Our definitions of non-GAAP adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings per share, free cash flow and constant currency sales growth may differ from that of other companies and therefore may not be comparable.
Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, health epidemics, pandemics and similar outbreaks, including the COVID-19 pandemic, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.
GLOBUS MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(unaudited)
|
|
||||||
|
|
Three Months Ended |
|||||
|
|
March 31, |
|||||
|
(In thousands, except per share amounts) |
2020 |
2019 |
||||
|
Sales |
$ |
190,577 |
$ |
182,947 | ||
|
Cost of goods sold |
48,864 | 41,838 | ||||
|
Gross profit |
141,713 | 141,109 | ||||
|
|
||||||
|
Operating expenses: |
||||||
|
Research and development |
15,402 | 14,324 | ||||
|
Selling, general and administrative |
93,539 | 85,784 | ||||
|
Amortization of intangibles |
3,776 | 3,343 | ||||
|
Acquisition related costs |
548 | 579 | ||||
|
Total operating expenses |
113,265 | 104,030 | ||||
|
|
||||||
|
Operating income |
28,448 | 37,079 | ||||
|
|
||||||
|
Other income, net |
||||||
|
Interest income/(expense), net |
4,324 | 4,159 | ||||
|
Foreign currency transaction gain/(loss) |
(468) | 189 | ||||
|
Other income/(expense) |
194 | 224 | ||||
|
Total other income/(expense), net |
4,050 | 4,572 | ||||
|
|
||||||
|
Income before income taxes |
32,498 | 41,651 | ||||
|
Income tax provision |
6,549 | 8,441 | ||||
|
|
||||||
|
Net income |
$ |
25,949 |
$ |
33,210 | ||
|
|
||||||
|
Earnings per share: |
||||||
|
Basic |
$ |
0.26 |
$ |
0.34 | ||
|
Diluted |
$ |
0.25 |
$ |
0.33 | ||
|
Weighted average shares outstanding: |
||||||
|
Basic |
99,635 | 98,727 | ||||
|
Dilutive stock options |
2,511 | 2,640 | ||||
|
Diluted |
102,146 | 101,367 | ||||
|
|
||||||
|
Anti-dilutive stock options excluded from weighted average calculation |
6,637 | 4,687 | ||||
GLOBUS MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)
|
|
||||||
|
|
March 31, |
December 31, |
||||
|
(In thousands, except par value) |
2020 |
2019 |
||||
|
ASSETS |
||||||
|
Current assets: |
||||||
|
Cash, cash equivalents, and restricted cash |
$ |
166,742 |
$ |
195,724 | ||
|
Short-term marketable securities |
110,211 | 115,763 | ||||
|
Accounts receivable, net of allowances of $6,760 and $5,599, respectively |
138,602 | 154,326 | ||||
|
Inventories |
208,451 | 196,314 | ||||
|
Prepaid expenses and other current assets |
17,713 | 17,243 | ||||
|
Income taxes receivable |
81 | 8,098 | ||||
|
Total current assets |
641,800 | 687,468 | ||||
|
Property and equipment, net of accumulated depreciation of $249,691 and $243,732, respectively |
212,605 | 199,841 | ||||
|
Long-term marketable securities |
380,061 | 409,514 | ||||
|
Intangible assets, net |
88,691 | 78,812 | ||||
|
Goodwill |
128,952 | 128,775 | ||||
|
Other assets |
20,568 | 21,741 | ||||
|
Deferred income taxes |
6,688 | 5,926 | ||||
|
Total assets |
$ |
1,479,365 |
$ |
1,532,077 | ||
|
|
||||||
|
LIABILITIES AND EQUITY |
||||||
|
Current liabilities: |
||||||
|
Accounts payable |
$ |
24,227 |
$ |
24,614 | ||
|
Accrued expenses |
60,052 | 63,283 | ||||
|
Income taxes payable |
898 | 1,057 | ||||
|
Business acquisition liabilities |
6,333 | 6,727 | ||||
|
Deferred revenue |
6,452 | 5,402 | ||||
|
Payable to broker |
- |
10,320 | ||||
|
Total current liabilities |
97,962 | 111,403 | ||||
|
Business acquisition liabilities, net of current portion |
3,156 | 2,822 | ||||
|
Deferred income taxes |
5,860 | 6,023 | ||||
|
Other liabilities |
9,021 | 9,377 | ||||
|
Total liabilities |
115,999 | 129,625 | ||||
|
Commitments and contingencies |
||||||
|
Equity: |
||||||
|
Class A common stock; $0.001 par value. Authorized 500,000 shares; issued and outstanding 75,664 and 77,395 shares at March 31, 2020 and December 31, 2019, respectively |
76 | 77 | ||||
|
Class B common stock; $0.001 par value. Authorized 275,000 shares; issued and outstanding 22,430 and 22,430 shares at March 31, 2020 and December 31, 2019, respectively |
22 | 22 | ||||
|
Additional paid-in capital |
369,984 | 357,320 | ||||
|
Accumulated other comprehensive loss |
(6,266) | (2,898) | ||||
|
Retained earnings |
999,550 | 1,047,931 | ||||
|
Total equity |
1,363,366 | 1,402,452 | ||||
|
Total liabilities and equity |
$ |
1,479,365 |
$ |
1,532,077 | ||
GLOBUS MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
|
|
||||||
|
|
Three Months Ended |
|||||
|
|
March 31, |
|||||
|
(In thousands) |
2020 |
2019 |
||||
|
Cash flows from operating activities: |
||||||
|
Net income |
$ |
25,949 |
$ |
33,210 | ||
|
Adjustments to reconcile net income to net cash provided by operating activities: |
||||||
|
Depreciation and amortization |
14,568 | 12,254 | ||||
|
Amortization of premium (discount) on marketable securities |
20 | (396) | ||||
|
Write-down for excess and obsolete inventories |
679 | 2,167 | ||||
|
Stock-based compensation expense |
6,807 | 6,448 | ||||
|
Allowance for doubtful accounts |
756 | 33 | ||||
|
Change in fair value of business acquisition liabilities |
506 | 579 | ||||
|
Change in deferred income taxes |
(2,895) | 1,059 | ||||
|
(Gain)/loss on disposal of assets, net |
207 | 94 | ||||
|
(Increase)/decrease in: |
||||||
|
Accounts receivable |
14,131 | (2,533) | ||||
|
Inventories |
(12,108) | (13,844) | ||||
|
Prepaid expenses and other assets |
(205) | 848 | ||||
|
Increase/(decrease) in: |
||||||
|
Accounts payable |
(283) | 2,827 | ||||
|
Accrued expenses and other liabilities |
(13,702) | (9,984) | ||||
|
Income taxes payable/receivable |
7,863 | 6,441 | ||||
|
Net cash provided by operating activities |
42,293 | 39,203 | ||||
|
Cash flows from investing activities: |
||||||
|
Purchases of marketable securities |
(57,418) | (127,911) | ||||
|
Maturities of marketable securities |
71,766 | 90,454 | ||||
|
Sales of marketable securities |
5,374 | 11,773 | ||||
|
Purchases of property and equipment |
(22,314) | (28,155) | ||||
|
Net cash used in investing activities |
(2,592) | (53,839) | ||||
|
Cash flows from financing activities: |
||||||
|
Payment of business acquisition liabilities |
(566) | (5,350) | ||||
|
Proceeds from exercise of stock options |
5,763 | 10,255 | ||||
|
Repurchase of common stock |
(73,864) |
— |
||||
|
Net cash provided by financing activities |
(68,667) | 4,905 | ||||
|
Effect of foreign exchange rate on cash |
(16) | (40) | ||||
|
Net increase in cash, cash equivalents, and restricted cash |
(28,982) | (9,771) | ||||
|
Cash, cash equivalents, and restricted cash at beginning of period |
195,724 | 139,747 | ||||
|
Cash, cash equivalents, and restricted cash at end of period |
$ |
166,742 |
$ |
129,976 | ||
|
Supplemental disclosures of cash flow information: |
||||||
|
Interest paid |
1 | 2 | ||||
|
Income taxes paid |
$ |
1,791 |
$ |
1,450 | ||
Supplemental Financial Information
Sales by Geographic Area:
|
|
||||||
|
|
Three Months Ended |
|||||
|
|
March 31, |
|||||
|
(In thousands) |
2020 |
2019 |
||||
|
United States |
$ |
158,447 |
$ |
147,536 | ||
|
International |
32,130 | 35,411 | ||||
|
Total Sales |
$ |
190,577 |
$ |
182,947 | ||
Sales by Revenue Stream:
|
|
||||||
|
|
Three Months Ended |
|||||
|
|
March 31, |
|||||
|
(In thousands) |
2020 |
2019 |
||||
|
Musculoskeletal Solutions products |
$ |
182,542 |
$ |
175,758 | ||
|
Enabling Technologies products |
8,035 | 7,189 | ||||
|
Total Sales |
$ |
190,577 |
$ |
182,947 | ||
Liquidity and Capital Resources:
|
|
||||||
|
|
March 31, |
December 31, |
||||
|
(In thousands) |
2020 |
2019 |
||||
|
Cash, cash equivalents, and restricted cash |
$ |
166,742 |
$ |
195,724 | ||
|
Short-term marketable securities |
110,211 | 115,763 | ||||
|
Long-term marketable securities |
380,061 | 409,514 | ||||
|
Total cash, cash equivalents, restricted cash and marketable securities |
$ |
657,014 |
$ |
721,001 | ||
The following tables reconcile GAAP to Non-GAAP financial measures.
Non-GAAP Adjusted EBITDA Reconciliation Table:
|
|
||||||
|
|
Three Months Ended |
|||||
|
|
March 31, |
|||||
|
(In thousands, except percentages) |
2020 |
2019 |
||||
|
Net income |
$ |
25,949 |
$ |
33,210 | ||
|
Interest income, net |
(4,324) | (4,159) | ||||
|
Provision for income taxes |
6,549 | 8,441 | ||||
|
Depreciation and amortization |
14,568 | 12,254 | ||||
|
EBITDA |
42,742 | 49,746 | ||||
|
Stock-based compensation expense |
6,807 | 6,448 | ||||
|
Acquisition related costs/licensing |
957 | 637 | ||||
|
Adjusted EBITDA |
$ |
50,506 |
$ |
56,831 | ||
|
|
||||||
|
Net income as a percentage of sales |
13.6% | 18.2% | ||||
|
Adjusted EBITDA as a percentage of sales |
26.5% | 31.1% | ||||
Non-GAAP Net Income Reconciliation Table:
|
|
||||||
|
|
Three Months Ended |
|||||
|
|
March 31, |
|||||
|
(In thousands) |
2020 |
2019 |
||||
|
Net income |
$ |
25,949 |
$ |
33,210 | ||
|
Amortization of intangibles |
3,776 | 3,343 | ||||
|
Acquisition related costs/licensing |
957 | 637 | ||||
|
Tax effect of adjusting items |
(956) | (807) | ||||
|
Non-GAAP net income |
$ |
29,726 |
$ |
36,383 | ||
Non-GAAP Diluted Earnings Per Share Reconciliation Table:
|
|
||||||
|
|
Three Months Ended |
|||||
|
|
March 31, |
|||||
|
(Per share amounts) |
2020 |
2019 |
||||
|
Diluted earnings per share, as reported |
$ |
0.25 |
$ |
0.33 | ||
|
Amortization of intangibles |
0.04 | 0.03 | ||||
|
Acquisition related costs/licensing |
0.01 | 0.01 | ||||
|
Tax effect of adjusting items |
(0.01) | (0.01) | ||||
|
Non-GAAP diluted earnings per share |
$ |
0.29 |
$ |
0.36 | ||
Non-GAAP Free Cash Flow Reconciliation Table:
|
|
||||||
|
|
Three Months Ended |
|||||
|
|
March 31, |
|||||
|
(In thousands) |
2020 |
2019 |
||||
|
Net cash provided by operating activities |
$ |
42,293 |
$ |
39,203 | ||
|
Purchases of property and equipment |
(22,314) | (28,155) | ||||
|
Free cash flow |
$ |
19,979 |
$ |
11,048 | ||
Non-GAAP Sales on a Constant Currency Basis Comparative Table:
|
|
|||||||||||||
|
|
Three Months Ended |
Reported |
Currency |
Constant |
|||||||||
|
|
March 31, |
Sales |
Current |
Sales |
|||||||||
|
(In thousands, except percentages) |
2020 |
2019 |
Growth |
Period Sales |
Growth |
||||||||
|
United States |
$ |
158,447 |
$ |
147,536 |
7.4% |
$ |
— |
7.4% |
|||||
|
International |
32,130 | 35,411 |
-9.3% |
(333) |
-8.3% |
||||||||
|
Total Sales |
$ |
190,577 |
$ |
182,947 |
4.2% |
$ |
(333) |
4.4% |
|||||
Contact:
Brian Kearns
Senior Vice President, Business Development and Investor Relations
Phone: (610) 930-1800
Email: investors@globusmedical.com
www.globusmedical.com